Wegovy and Ozempic tied to dramatically lower cancer deaths

Wegovy and Ozempic tied to dramatically lower cancer deaths

GLP-1 drugs such as Ozempic and Wegovy may extend the lives of colon cancer patients, according to a major UC San Diego study. Patients on the medications had less than half the mortality rate of non-users. Researchers suspect the drugs’ anti-inflammatory and metabolic effects contribute to improved outcomes. They’re now calling for clinical trials to test whether these findings reflect a true anti-cancer mechanism.